Literature DB >> 21194018

Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles.

Charis L Himeda1, Xiaolan Chen, Stephen D Hauschka.   

Abstract

Gene therapy for muscular dystrophies requires efficient gene delivery to the striated musculature and specific, high-level expression of the therapeutic gene in a physiologically diverse array of muscles. This can be achieved by the use of recombinant adeno-associated virus vectors in conjunction with muscle-specific regulatory cassettes. We have constructed several generations of regulatory cassettes based on the enhancer and promoter of the muscle creatine kinase gene, some of which include heterologous enhancers and individual elements from other muscle genes. Since the relative importance of many control elements varies among different anatomical muscles, we are aiming to tailor these cassettes for high-level expression in cardiac muscle, and in fast and slow skeletal muscles. With the achievement of efficient intravascular gene delivery to isolated limbs, selected muscle groups, and heart in large animal models, the design of cassettes optimized for activity in different muscle types is now a practical goal. In this protocol, we outline the key steps involved in the design of regulatory cassettes for optimal activity in skeletal and cardiac muscle, and testing in mature muscle fiber cultures. The basic principles described here can also be applied to engineering tissue-specific regulatory cassettes for other cell types.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21194018     DOI: 10.1007/978-1-61737-982-6_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  19 in total

1.  Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophy.

Authors:  Jinhong Meng; Marc Moore; John Counsell; Francesco Muntoni; Linda Popplewell; Jennifer Morgan
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-02       Impact factor: 5.849

2.  Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.

Authors:  Nicholas P Whitehead; Kenneth L Bible; Min Jeong Kim; Guy L Odom; Marvin E Adams; Stanley C Froehner
Journal:  J Physiol       Date:  2016-10-13       Impact factor: 5.182

Review 3.  Progress and prospects of gene therapy clinical trials for the muscular dystrophies.

Authors:  Niclas E Bengtsson; Jane T Seto; John K Hall; Jeffrey S Chamberlain; Guy L Odom
Journal:  Hum Mol Genet       Date:  2015-10-08       Impact factor: 6.150

4.  Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice.

Authors:  Chuhong Hu; Jennifer Kasten; Hana Park; Ragini Bhargava; Denise S Tai; Wayne W Grody; Quynh G Nguyen; Stephen D Hauschka; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2014-06-03       Impact factor: 11.454

5.  Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.

Authors:  Adrian Pickar-Oliver; Veronica Gough; Joel D Bohning; Siyan Liu; Jacqueline N Robinson-Hamm; Heather Daniels; William H Majoros; Garth Devlin; Aravind Asokan; Charles A Gersbach
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 12.910

6.  Treatment of hypophosphatasia by muscle-directed expression of bone-targeted alkaline phosphatase via self-complementary AAV8 vector.

Authors:  Aki Nakamura-Takahashi; Koichi Miyake; Atsushi Watanabe; Yukihiko Hirai; Osamu Iijima; Noriko Miyake; Kumi Adachi; Yuko Nitahara-Kasahara; Hideaki Kinoshita; Taku Noguchi; Shinichi Abe; Sonoko Narisawa; Jose Luis Millán; Takashi Shimada; Takashi Okada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-02-03       Impact factor: 6.698

7.  A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy.

Authors:  Chady H Hakim; Nalinda B Wasala; Xiufang Pan; Kasun Kodippili; Yongping Yue; Keqing Zhang; Gang Yao; Brittney Haffner; Sean X Duan; Julian Ramos; Joel S Schneider; N Nora Yang; Jeffrey S Chamberlain; Dongsheng Duan
Journal:  Mol Ther Methods Clin Dev       Date:  2017-07-27       Impact factor: 6.698

8.  Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.

Authors:  Niclas E Bengtsson; John K Hall; Guy L Odom; Michael P Phelps; Colin R Andrus; R David Hawkins; Stephen D Hauschka; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Nat Commun       Date:  2017-02-14       Impact factor: 14.919

Review 9.  Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Dongsheng Duan
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

Review 10.  Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.

Authors:  Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Hum Genet       Date:  2016-08-20       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.